Transforming Early Cancer Detection
Innovative Solutions for Rapid Cancer Testing
Rapid Test Kits for Early Cancer Diagnosis – Detect cancer swiftly and accurately.
Impact Metrics of Early Cancer Rapid Testing…
Explore how our early rapid cancer testing is changing lives.
earlycancerdetectiontest #rapidcancertestkit #cancerscreeningtestkit #homecancertest #cancerdetectionkit #tumormarkertestkit #pointofcarecancertest #lateralflowcancertest #fastcancerdiagnosis #bloodtestforcancerdetection
Patients diagnosed at Stage I have significantly higher 5-year survival rates compared to late-stage diagnoses—often exceeding 90% for cancers like breast, cervical, and colorectal.
Early-stage interventions cost dramatically less than managing metastatic cancer, reducing the financial burden on healthcare systems, especially in low-resource settings.
Rapid, point-of-care tests enable deployment in rural and underserved regions, expanding screening coverage where traditional lab infrastructure is limited or unavailable.
Transforming Rapid Cancer Detection
Early Diagnosis = Better Outcomes
Results in 20 Minutes or Less
Ideal for Mass Screening Programs
Use Anywhere – Point of Care or Remote
No Lab or Equipment Needed
Cost-Effective & Scalable
Non-Invasive Sample Collection
Cost-Effective Solutions
Ideal for Mass Screening Programs
Use Anywhere – Point of Care or Remote
Early detection saves lives. OncoFirm Diagnostics is at the forefront of rapid early cancer screening, delivering innovative diagnostic test kits that detect tumor-specific biomarkers in 10–20 minutes—with no lab or specialized equipment required.
Innovative Programs in Cancer Testing Solutions
Rapid early cancer screening refers to real-time testing tools that identify cancer-related biomarkers at the earliest and most treatable stages. Unlike traditional lab-based methods, our rapid tests use lateral flow assay (LFA) or immunodiagnostic platforms for fast, accurate, and accessible cancer detection.
Explore Our Early Rapid Cancer Testing Products
Our screening portfolio includes kits under development or in clinical use for:
Breast Cancer – HER2, CA15-3
Prostate Cancer – PSA, PAP
Colorectal Cancer – CEA, CA19-9
Ovarian Cancer – CA125
Lung Cancer – CYFRA 21-1, NSE
Pancreatic Cancer – CA19-9, CEA
OncoFirm continues to expand biomarker coverage based on the latest oncology research and clinical validation data.
Impact Metrics of Early Cancer Screening Tests…
Explore how our rapid cancer testing is changing lives.
OncoFirm’s Cancer Rapid Tests are dedicated to revolutionizing early cancer diagnostics with rapid, affordable testing solutions that empower both patients and clinicians.
Our innovative tests enable quick results, facilitating timely intervention and improving patient outcomes.
We specialize in point-of-care cancer testing solutions.
Participate in Our Exciting Events
Join us to advance cancer detection and diagnosis.
Engage with Our Community
Your participation can help save lives and improve outcomes.
Take Action Today!
Start Your Early Cancer Detection Journey Now!